Business Description
enVVeno Medical Corp
NAICS : 339113
SIC : 3841
ISIN : US29415J1060
Share Class Description:
FRA:5HJ: Ordinary SharesDescription
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 31.69 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 33.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35.8 | |||||
| 3-Year FCF Growth Rate | 36.8 | |||||
| 3-Year Book Growth Rate | 7.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.81 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.17 | |||||
| 9-Day RSI | 54.47 | |||||
| 14-Day RSI | 51.83 | |||||
| 6-1 Month Momentum % | -8.08 | |||||
| 12-1 Month Momentum % | -8.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 23.33 | |||||
| Quick Ratio | 23.33 | |||||
| Cash Ratio | 23.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -73.7 | |||||
| Shareholder Yield % | 0.45 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -56.99 | |||||
| ROA % | -52.91 | |||||
| ROIC % | -904.3 | |||||
| 3-Year ROIIC % | -3049.81 | |||||
| ROC (Joel Greenblatt) % | -1341.57 | |||||
| ROCE % | -60.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.85 | |||||
| Price-to-Tangible-Book | 1.84 | |||||
| EV-to-EBIT | -1.46 | |||||
| EV-to-EBITDA | -1.5 | |||||
| EV-to-FCF | -1.98 | |||||
| Price-to-Net-Current-Asset-Value | 1.92 | |||||
| Price-to-Net-Cash | 1.94 | |||||
| Earnings Yield (Greenblatt) % | -68.49 | |||||
| FCF Yield % | -23.51 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers